IR
IRIX.US IRIDEX Corporation
- Market cap
- USD 12.1M
- P/E
- -
- P/B
- 331.20x
- ROE
- -98.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IRIX.US undervalued?
Graham numberThe Graham number of IRIDEX Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IRIDEX Corporation fundamental analysis
No fundamental analysis for IRIDEX Corporation yet.
IRIDEX Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photoc…
Full company profileIRIDEX Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IRIDEX Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 46.2M | 41.6M | 42.6M | 43.4M | 36.3M | 53.9M | 57.0M | 51.9M | 48.7M | 52.7M | 48.7M |
| Gross Profit | 20.8M | 15.5M | 17.5M | 17.9M | 15.6M | 22.8M | 25.4M | 21.8M | 19.5M | 19.3M | 18.1M |
| Operating Income | -2.57M | -12.9M | -12.9M | -8.97M | -6.58M | -7.53M | -7.54M | -10.0M | -8.30M | -2.57M | -2.71M |
| EBITDA | -1.80M | -12.2M | -12.1M | -8.29M | -6.08M | -6.73M | -6.16M | -7.45M | -7.42M | -2.83M | -1.52M |
| Net Income | -11.7M | -12.9M | -12.8M | -8.81M | -6.33M | -5.23M | -7.55M | -9.57M | -8.91M | -4.44M | -3.58M |
| EPS | -1.15 | -1.11 | -1.05 | -0.64 | -0.46 | -0.34 | -0.47 | -0.59 | -0.54 | -0.26 | -0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 48.1M | 41.6M | 41.7M | 34.8M | 28.0M | 48.7M | 42.3M | 34.4M | 29.1M | 29.2M | 27.3M |
| Total Liabilities | 8.98M | 11.1M | 11.7M | 12.1M | 10.6M | 25.4M | 25.1M | 24.9M | 27.0M | 24.2M | 23.6M |
| Shareholders' Equity | 39.2M | 30.5M | 30.0M | 22.7M | 17.4M | 23.3M | 17.2M | 9.52M | 2.10M | 4.92M | 3.64M |
| Cash & Short-term Investments | 23.7M | 21.7M | 21.2M | 12.7M | 11.6M | 23.9M | 13.9M | 7.03M | 2.39M | 6.03M | 4.68M |
| Total Debt | - | - | - | 3.21M | 4.19M | 2.66M | 1.77M | 2.75M | 4.64M | 4.53M | 4.01M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -144K | -3.57M | -10.0M | -7.91M | -3.24M | 8.22M | -9.52M | -6.75M | -7.29M | -2.12M | -2.32M |
| Capital Expenditure | 1.06M | 575K | 440K | 128K | 97.0K | 213K | 286K | 109K | 13.0K | 143K | 302K |
| Free Cash Flow | -1.21M | -4.14M | -10.5M | -8.04M | -3.33M | 8.00M | -9.81M | -6.85M | -7.30M | -2.26M | -2.62M |
| Ratios | |||||||||||
| ROE | -29.9% | -42.2% | -42.8% | -38.8% | -36.4% | -22.4% | -43.8% | -100.5% | -424.9% | -90.1% | -98.4% |
| ROA | -24.3% | -30.9% | -30.7% | -25.3% | -22.6% | -10.7% | -17.8% | -27.8% | -30.6% | -15.2% | -13.1% |
| Net Profit Margin | -25.4% | -30.9% | -30.1% | -20.3% | -17.4% | -9.7% | -13.2% | -18.5% | -18.3% | -8.4% | -7.3% |
| Debt to Equity | - | - | - | 0.14x | 0.24x | 0.11x | 0.10x | 0.29x | 2.21x | 0.92x | 1.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IRIDEX Corporation dividends
IRIDEX Corporation has not paid dividends in the last 9 fiscal years.
Who owns IRIDEX Corporation
- Insiders 37.52%
- Institutions 18.05%
- Public & others 44.43%
- Shares outstanding 17.6M
- Free float 10.0M
Top funds holding IRIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 402K | 2.29% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 72.0K | 0.41% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 16.9K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 14.5K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 11.3K | 0.06% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 3.96K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding IRIX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 515K | 2.93% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 333K | 1.90% | -21.32% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 305K | 1.74% | 0.00% | Jun 2026 |
| Weber Capital Management LLC | 147K | 0.84% | -18.55% | Sep 2026 |
| Geode Capital Management, LLC | 139K | 0.79% | -13.24% | Jun 2026 |
| Citadel Advisors Llc | 99.0K | 0.56% | +62.61% | Jun 2026 |
| Perkins Capital Management Inc | 70.8K | 0.40% | +28.03% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 60.2K | 0.34% | 0.00% | Jun 2026 |
| State Street Corp | 44.7K | 0.25% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 40.5K | 0.23% | +7.53% | Jun 2026 |
| United Capital Financial Advisers Inc | 35.5K | 0.20% | -38.24% | Jun 2026 |
| DIVERSIFY WEALTH MANAGEMENT, LLC | 33.8K | 0.19% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 29.2K | 0.17% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 27.5K | 0.16% | -5.05% | Jun 2026 |
| Bank of New York Mellon Corp | 25.6K | 0.15% | 0.00% | Jun 2026 |
| Northern Trust Corp | 24.0K | 0.14% | +12.55% | Jun 2026 |
| BlackRock Inc | 20.3K | 0.12% | 0.00% | Jun 2026 |
| Thompson Davis & Co Inc | 15.4K | 0.09% | -67.45% | Jun 2026 |
| Citigroup Inc | 14.2K | 0.08% | 0.00% | Jun 2026 |
| Centiva Capital LP | 13.9K | 0.08% | 0.00% | Jun 2026 |
IRIDEX Corporation company profile
- Company name
- IRIDEX Corporation
- Ticker
- IRIX.US
- Exchange
- USA Stocks
- Listed since
- Feb 15, 1996
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 93
- Fiscal year end
- December
- Address
- 1212 Terra Bella Avenue, Mountain View, CA, United States, 94043
- Phone
- 650 940 4700
- Website
- iridex.com
About IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
IRIDEX Corporation management
5- Mr. Scott A. Shuda J.D.Executive Chairman · born 1965
- Mr. Patrick MercerCEO, President & Director · born 1972
- Mr. Romeo R. DizonChief Financial Officer · born 1958
- Mr. Bassem BouHabibSVP of International Sales & Business Development · born 1976
- Ms. Leigh SalvoHead of Investor Relations